Potassium Iodide Use and Patient Outcomes for Thyroid Storm: An Observational Study
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae187 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Yuichiro Matsuo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, 113-8655, Japan. Hauptthemen laut MEDLINE: Potassium Iodide, Thyroid Crisis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Ministry of Health, Labor, and Welfare of Japan.
Abstract (Originalsprache)
Context
Iodine, combined with antithyroid drugs, is recommended as an initial pharmacologic treatment for thyroid storm according to some clinical guidelines. However, the clinical efficacy of iodine in managing thyroid storm remains unexplored.
Objective
This study aimed to determine whether early potassium iodide (KI) use is associated with mortality in patients hospitalized for thyroid storm.
Methods
Using the Japanese Diagnosis Procedure Combination database, we identified patients hospitalized with thyroid storm between July 2010 and March 2022. We compared in-hospital mortality, length of stay, and total hospitalization costs between patients who received KI within 2 days of admission (KI group) vs those who did not (non-KI group). Prespecified subgroup analyses were performed based on the presence of the diagnosis of Graves’ disease.
Results
Among 3188 eligible patients, 2350 received KI within 2 days of admission. The crude in-hospital mortality was 6.1% (143/2350) in the KI group and 7.8% (65/838) in the non-KI group. After adjusting for potential confounders, KI use was not significantly associated with in-hospital mortality (odds ratio [OR] for KI use, 0.91; 95% CI, 0.62-1.34). In patients with the diagnosis of Graves’ disease, in-hospital mortality was lower in the KI group than in the non-KI group (OR, 0.46; 95% CI, 0.25-0.88). No significant difference in in-hospital mortality was observed in patients without the diagnosis of Graves’ disease (OR, 1.11; 95% CI, 0.67-1.85). Length of stay was shorter (subdistribution hazard ratio, 1.15; 95% CI, 1.05-1.27), and total hospitalization costs were lower (OR, 0.92; 95% CI, 0.85-1.00) in the KI group compared with the non-KI group.
Conclusion
Our findings suggest that KI may reduce in-hospital mortality among patients hospitalized for thyroid storm with Graves’ disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, 113-8655, Japan.
- Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.
- Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
ORCID-Profile: Yuichiro Matsuo
Förderung
- Ministry of Health, Labor, and Welfare of Japan
Zitieren
APA
Matsuo, Y., Miyawaki, A., Watanabe, H., Matsui, H., Fushimi, K., & Yasunaga, H. (2025). Potassium Iodide Use and Patient Outcomes for Thyroid Storm: An Observational Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae187
Vancouver
Matsuo Y, Miyawaki A, Watanabe H, Matsui H, Fushimi K, Yasunaga H. Potassium Iodide Use and Patient Outcomes for Thyroid Storm: An Observational Study. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae187
BibTeX
@article{Matsuo2025,
author = {Matsuo, Yuichiro and Miyawaki, Atsushi and Watanabe, Hideaki and Matsui, Hiroki and Fushimi, Kiyohide and Yasunaga, Hideo},
title = {Potassium Iodide Use and Patient Outcomes for Thyroid Storm: An Observational Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae187}
}
EUVIMED